Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor? JACC Review Topic of the Week

Diana Gorog, Gregory Y H Lip

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)
6 Downloads (Pure)

Abstract

Endogenous fibrinolysis is a powerful natural defense mechanism against lasting arterial thrombotic occlusion. Recent prospective studies have shown that impaired endogenous fibrinolysis (or hypofibrinolysis) can be detected in a significant number of patients with acute coronary syndrome (ACS) using global assays and is a strong marker of future cardiovascular risk. This novel risk biomarker is independent of traditional cardiovascular risk factors and unaffected by antiplatelet therapy. Most prospective prognostic data have been obtained using a global assay using native whole blood at high shear or plasma turbidimetric assays, which are described herein. Tests of endogenous fibrinolysis could be used to identify patients with ACS who, despite antiplatelet therapy, remain at high cardiovascular risk. This review discusses the impact of currently available medications and those in development that favorably modulate fibrinolytic status and may offer a potential new avenue to improve outcomes in ACS.

Original languageEnglish
Pages (from-to)1366-1375
Number of pages10
JournalJournal of the American College of Cardiology
Volume74
Issue number10
Early online date2 Sept 2019
DOIs
Publication statusPublished - 10 Sept 2019

Keywords

  • acute coronary syndrome
  • fibrinolysis
  • risk factor
  • thrombolysis
  • thrombosis

Fingerprint

Dive into the research topics of 'Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor? JACC Review Topic of the Week'. Together they form a unique fingerprint.

Cite this